Oxulumis®, Suprachoroidal Drug Administration of Triesence® in Diabetic Macular Edema

NCT05172401 · clinicaltrials.gov ↗
NA
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped unforeseen, continued (\>12month) global shortage of study medication. Study Drug Triesence, manufacturer Novartis, not supplied throughout 2022

Conditions

Interventions

Sponsor

Oxular Limited